Search results for "Venlafaxine"

showing 10 items of 20 documents

QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients

2018

Abstract Introduction Many antidepressants cause QT prolongation but the classification of cardiac risk of these drugs varies markedly in different published lists. This retrospective study analyzed the correlation of QTc time with amitriptyline and venlafaxine serum level in elderly psychiatric inpatients. Methods Elderly inpatients aged≥65 years for whom venlafaxine or amitriptyline serum level had been measured were selected retrospectively from a therapeutic drug monitoring database and screened for an electrocardiogram measurement at the time of blood withdrawal. The correlation of amitriptyline or venlafaxine serum levels with QTc time was examined by using Pearson’s correlation analy…

MaleDrugmedicine.medical_specialtyDatabases FactualAmitriptylinemedia_common.quotation_subjectVenlafaxineQT intervalElectrocardiography03 medical and health sciences0302 clinical medicineTherapeutic indexPharmacokineticsmedicineHumansPharmacology (medical)Amitriptyline030212 general & internal medicinePsychiatryAgedRetrospective Studiesmedia_commonAged 80 and overInpatientsmedicine.diagnostic_testbusiness.industryVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineAntidepressive AgentsLong QT SyndromePsychiatry and Mental healthTherapeutic drug monitoringFemalebusiness030217 neurology & neurosurgerymedicine.drugPharmacopsychiatry
researchProduct

Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein

2010

According to in vitro studies the enantiomers of venlafaxine display different degrees of serotonin and noradrenaline reuptake inhibition. Therefore, clarification of the enantiomeric drug distribution between serum and brain is highly warranted. To elucidate if P-glycoprotein (P-gp) in a stereoselective manner transports venlafaxine and its metabolites out of the brain we used abcb1ab double-knockout mice that do not express P-gp. A single dose of racemic venlafaxine (10 mg/kg bw) was intraperitoneally injected to knockout (-/-) and wildtype (+/+) mice. Serum and brain samples were collected 1, 3, 6 and 9 h following drug administration for analysis by LC/MS/MS. One to six hours post-dose,…

MaleMedicin och hälsovetenskapVenlafaxinePharmacologyBlood–brain barrierMedical and Health SciencesMicemedicineAnimalsPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Biological PsychiatryP-glycoproteinPharmacologyMice KnockoutbiologyChemistryVenlafaxine HydrochlorideBiological TransportStereoisomerismCyclohexanolsIn vitroPsychiatry and Mental healthmedicine.anatomical_structureNeurologyBlood-Brain BarrierKnockout mousebiology.proteinStereoselectivityNeurology (clinical)SerotoninEnantiomerSelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Risk of bleeding related to selective and non-selective serotonergic antidepressants: a case/non-case approach using data from two pharmacovigilance …

2014

There is increasing evidence for an association between treatment with selective serotonin reuptake inhibitors (SSRI) and an increased risk of bleeding events. The most important underlying mechanism appears to be inhibition of serotonin uptake in platelets, an effect that is also present in antidepressants with non-selective serotonin-reuptake inhibition (NSRI). Accordingly, also NSRI may be associated with an increased risk of bleeding. However, there is little data in this regard.Based on data (spontaneous reports of adverse drug reactions) from 2 pharmacovigilance databases (WHO-database/Vigibase™; BfArM/AkdÄ-database in Germany) we used a case/non-case approach and calculated reporting…

MaleSerotonin uptakeDatabases FactualDrug-Related Side Effects and Adverse ReactionsVenlafaxineHemorrhageSerotonergiccomputer.software_genrePharmacovigilanceDiclofenacSerotonin AgentsSerotonin AgentsGermanyPharmacovigilanceMedicineHumansPharmacology (medical)Databasebusiness.industryDepressionGeneral MedicineOdds ratioAntidepressive AgentsPsychiatry and Mental healthFemalebusinessReuptake inhibitorcomputermedicine.drugPharmacopsychiatry
researchProduct

Bioavailability of pharmaceuticals in waters close to wastewater treatment plants: Use of fish bile for exposure assessment

2012

Pharmaceuticals are ubiquitous in surface waters as a consequence of discharges from municipal wastewater treatment plants. However, few studies have assessed the bioavailability of pharmaceuticals to fish in natural waters. In the present study, passive samplers and rainbow trout were experimentally deployed next to three municipal wastewater treatment plants in Finland to evaluate the degree of animal exposure. Pharmaceuticals from several therapeutic classes (in total 15) were analyzed by liquid chromatography-tandem mass spectrometry in extracts of passive samplers and in bile and blood plasma of rainbow trout held at polluted sites for 10 d. Each approach indicated the highest exposure…

Maleendocrine systemDiclofenacanimal structuresHealth Toxicology and MutagenesisMetaboliteAnti-Inflammatory AgentsBiological AvailabilityIbuprofenCitalopramWastewaterdigestive systemPolar organic chemical integrative samplerPlasmaVitellogeninchemistry.chemical_compoundNaproxenAnimalsBileEnvironmental ChemistryFinland630 AgriculturebiologyChemistryVenlafaxine HydrochlorideCyclohexanolsbiology.organism_classificationBioavailabilityTroutCarbamazepineLiverWastewaterOncorhynchus mykissEnvironmental chemistrybiology.proteinSewage treatmentRainbow troutWater Pollutants ChemicalChromatography LiquidEnvironmental Toxicology and Chemistry
researchProduct

2020

Withdrawal symptoms after discontinuation of antidepressants are common and have long been known. Typical symptoms after dose reduction or discontinuation of antidepressants are dizziness, drowsiness, headache, flu-like symptoms, hyperarousal, imbalance, insomnia, irritability, and nausea. Rebound, relapse, or recurrence associated with the underlying mental disorder may also occur. The occurrence of obsessive-compulsive symptoms (OCS) following abrupt discontinuation of antidepressants have not yet been reported. Here we report the development of OCS (obsessional suicidal thoughts) in a patient with major depressive disorder and absence of a previous obsessive-compulsive disorder following…

Pediatricsmedicine.medical_specialtyNauseabusiness.industryVenlafaxinemedicine.diseaseIrritabilityObsessive compulsive symptoms030227 psychiatryDiscontinuation03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinemedicineEscitalopramMajor depressive disordermedicine.symptombusiness030217 neurology & neurosurgeryDepression (differential diagnoses)medicine.drugFrontiers in Psychiatry
researchProduct

An overview of the clinical efficacy of mirtazapine

2002

Mirtazapine is at least as effective as the tricyclic antidepressants and trazodone in a wide range of patient subgroups including in- and out-patients with moderate to severe depression. It also appears to be at least as effective as the serotonin and noradrenaline reuptake inhibitor venlafaxine in the treatment of severely depressed melancholic patients. When compared with the selective serotonin reuptake inhibitors (SSRIs), mirtazapine shows a significantly earlier onset of action. Further analysis of a study comparing mirtazapine with the SSRI paroxetine indicated that early improvement was a highly sensitive predictor of later stable response for both drugs. The positive predictive val…

Time FactorsMirtazapineVenlafaxine HydrochlorideMirtazapineVenlafaxineMianserinAntidepressive Agents TricyclicPharmacologymedicineHumansPharmacology (medical)chemistry.chemical_classificationClinical Trials as TopicDepressive DisorderAdrenergic Uptake Inhibitorsbusiness.industryVenlafaxine HydrochlorideTrazodoneCyclohexanolsParoxetineAntidepressive AgentsParoxetinePsychiatry and Mental healthTreatment OutcomeNeurologychemistryNeurology (clinical)SerotoninOnset of actionbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTricyclicHuman Psychopharmacology: Clinical and Experimental
researchProduct

Pharmacologic Approaches to CDH: Evidence and Outcomes

2018

Chronic daily headache (CDH) is a highly prevalent condition that severely affects patient’s lives. Most patients with CDH experience chronic migraine (CM). The management of these patients is complex and includes acute and preventive pharmacological treatment. In CDH, the use of acute medication should be restricted to avoid the risk of medication-overuse headache. However, the use of preventive medication should be considered in all patients with CDH. There are few studies investigating the role of preventives in CDH, and the majority have CM. Topiramate and onabotulinumtoxinA are the only two drugs with proved scientific evidence in the prevention of CM. There are other neuromodulators, …

Topiramatemedicine.medical_specialtyFluoxetineeducation.field_of_studyGabapentinbusiness.industryPopulationVenlafaxineChronic MigraineInternal medicinemedicineAmitriptylinebusinesseducationFlunarizinemedicine.drug
researchProduct

Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?

1997

The purpose of this article is to compare and contrast the benefits and limitations of antidepressant drugs. Several different classes of antidepressants are available for treatment of major depressive disorder, each with its own benefits and limitations as a result of its pharmacological profile. Tricyclic antidepressants (TCAs) and monoamine oxidase (MAO) inhibitors are effective in a large proportion of depressed patients, but their use is often limited by short- and long-term safety/tolerability problems. Selective serotonin reuptake inhibitors (SSRIs) exhibit comparable efficacy to TCAs in most patients, but may be less effective in certain patients. Additionally, SSRI use may by impac…

chemistry.chemical_classificationbusiness.industryVenlafaxinePharmacologymedicine.diseasePsychiatry and Mental healthNeurologychemistryTolerabilitymedicineAntidepressantMajor depressive disorderAnxietyPharmacology (medical)Neurology (clinical)Onset of actionmedicine.symptomReuptake inhibitorbusinessTricyclicmedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Severe Tremor After Cotrimoxazole-Induced Elevation of Venlafaxine Serum Concentrations in a Patient With Major Depressive Disorder

2013

: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 d…

medicine.medical_specialtyCYP2D6Venlafaxine HydrochlorideVenlafaxineCYP2C19Severity of Illness IndexGastroenterologyAnti-Infective AgentsInternal medicineTremorTrimethoprim Sulfamethoxazole Drug CombinationHumansMedicineDrug InteractionsPharmacology (medical)PsychiatryCYP2C9PharmacologyDepressive Disorder MajorCYP3A4business.industryVenlafaxine HydrochlorideMiddle AgedCyclohexanolsmedicine.diseaseTrimethoprimCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Major depressive disorderFemaleAryl Hydrocarbon HydroxylasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic Drug Monitoring
researchProduct

Efficacy and tolerance of a medication switch from Escitalopram to Venlafaxine in patients with Major Depressive Disorders

2017

medicine.medical_specialtybusiness.industrymedicineEscitalopramVenlafaxineIn patientPsychiatrybusinessmedicine.drugPharmacopsychiatry
researchProduct